|
1
|
Chin D, Boyle GM, Porceddu S, Theile DR,
Parsons PG and Coman WB: Head and neck cancer: Past, present and
future. Expert Rev Anticancer Ther. 6:1111–1118. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Molinolo AA, Amornphimoltham P, Squarize
CH, Castilho RM, Patel V and Gutkind JS: Dysregulated molecular
networks in head and neck carcinogenesis. Oral Oncol. 45:324–334.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rane SG and Reddy EP: Janus kinases:
Components of multiple signaling pathways. Oncogene. 19:5662–5679.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Song JI and Grandis JR: STAT signaling in
head and neck cancer. Oncogene. 19:2489–2495. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kijima T, Niwa H, Steinman RA, Drenning
SD, Gooding WE, Wentzel AL, Xi S and Grandis JR: STAT3 activation
abrogates growth factor dependence and contributes to head and neck
squamous cell carcinoma tumor growth in vivo. Cell Growth Differ.
13:355–362. 2002.PubMed/NCBI
|
|
6
|
Leeman RJ, Lui VW and Grandis JR: STAT3 as
a therapeutic target in head and neck cancer. Expert Opin Biol
Ther. 6:231–241. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bromberg J: Stat proteins and oncogenesis.
J Clin Invest. 109:1139–1142. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jewett A, Head C and Cacalano NA: Emerging
mechanisms of immunosuppression in oral cancers. J Dent Res.
85:1061–1073. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lai SY and Johnson FM: Defining the role
of the JAK-STAT pathway in head and neck and thoracic malignancies:
Implications for future therapeutic approaches. Drug Resist Updat.
13:67–78. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Naher L, Kiyoshima T, Kobayashi I, Wada H,
Nagata K, Fujiwara H, Ookuma YF, Ozeki S, Nakamura S and Sakai H:
STAT3 signal transduction through interleukin-22 in oral squamous
cell carcinoma. Int J Oncol. 41:1577–1586. 2012.PubMed/NCBI
|
|
11
|
Bromberg J and Darnell JE Jr: The role of
STATs in transcriptional control and their impact on cellular
function. Oncogene. 19:2468–2473. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Decker T and Kovarik P: Serine
phosphorylation of STATs. Oncogene. 19:2628–2637. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chung J, Uchida E, Grammer TC and Blenis
J: STAT3 serine phosphorylation by ERK-dependent and -independent
pathways negatively modulates its tyrosine phosphorylation. Mol
Cell Biol. 17:6508–6516. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Reich NC and Liu L: Tracking STAT nuclear
traffic. Nat Rev Immunol. 6:602–612. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lim CP and Cao X: Serine phosphorylation
and negative regulation of Stat3 by JNK. J Biol Chem.
274:31055–31061. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Venkatasubbarao K, Choudary A and Freeman
JW: Farnesyl transferase inhibitor (R115777)-induced inhibition of
STAT3 (Tyr705) phosphorylation in human pancreatic cancer cell
lines require extracellular signal-regulated kinases. Cancer Res.
65:2861–2871. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wakahara R, Kunimoto H, Tanino K, Kojima
H, Inoue A, Shintaku H and Nakajima K: Phospho-Ser727 of STAT3
regulates STAT3 activity by enhancing dephosphorylation of
phospho-Tyr705 largely through TC45. Genes Cells. 17:132–145. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sakaguchi M, Oka M, Iwasaki T, Fukami Y
and Nishigori C: Role and regulation of STAT3 phosphorylation at
Ser727 in melanocytes and melanoma cells. J Invest Dermatol.
132:1877–1885. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Aggarwal BB, Kunnumakkara AB, Harikumar
KB, Gupta SR, Tharakan ST, Koca C, Dey S and Sung B: Signal
transducer and activator of transcription-3, inflammation, and
cancer: How intimate is the relationship? Ann N Y Acad Sci.
1171:59–76. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Johnson GL and Lapadat R:
Mitogen-activated protein kinase pathways mediated by ERK, JNK, and
p38 protein kinases. Science. 298:1911–1912. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Maggioni D, Gaini R, Nicolini G, Tredici G
and Garavello W: MAPKs activation in head and neck squamous cell
carcinomas. Oncol Rev. 5:223–231. 2011. View Article : Google Scholar
|
|
22
|
Kim TW, Michniewicz M, Bergmann DC and
Wang ZY: Brassinosteroid regulates stomatal development by
GSK3-mediated inhibition of a MAPK pathway. Nature. 482:419–422.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kim JY, An JM, Chung WY, Park KK, Hwang
JK, Kim DS, Seo SR and Seo JT: Xanthorrhizol induces apoptosis
through ROS-mediated MAPK activation in human oral squamous cell
carcinoma cells and inhibits DMBA-induced oral carcinogenesis in
hamsters. Phytother Res. 27:493–498. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li B, Lu L, Zhong M, Tan XX, Liu CY, Guo Y
and Yi X: Terbinafine inhibits KSR1 and suppresses Raf-MEK-ERK
signaling in oral squamous cell carcinoma cells. Neoplasma.
60:406–412. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wada T and Penninger JM: Mitogen-activated
protein kinases in apoptosis regulation. Oncogene. 23:2838–2849.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Boivin A, Hanot M, Malesys C, Maalouf M,
Rousson R, Rodriguez-Lafrasse C and Ardail D: Transient alteration
of cellular redox buffering before irradiation triggers apoptosis
in head and neck carcinoma stem and non-stem cells. PLoS One.
6:e145582011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gross ND, Boyle JO, Du B, Kekatpure VD,
Lantowski A, Thaler HT, Weksler BB, Subbaramaiah K and Dannenberg
AJ: Inhibition of Jun NH2-terminal kinases suppresses the growth of
experimental head and neck squamous cell carcinoma. Clin Cancer
Res. 13:5910–5917. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yunoki T, Kariya A, Kondo T, Hayashi A and
Tabuchi Y: The combination of silencing BAG3 and inhibition of the
JNK pathway enhances hyperthermia sensitivity in human oral
squamous cell carcinoma cells. Cancer Lett. 335:52–57. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ahmed ST, Mayer A, Ji JD and Ivashkiv LB:
Inhibition of IL-6 signaling by a p38-dependent pathway occurs in
the absence of new protein synthesis. J Leukoc Biol. 72:154–162.
2002.PubMed/NCBI
|
|
30
|
Jain N, Zhang T, Fong SL, Lim CP and Cao
X: Repression of Stat3 activity by activation of mitogen-activated
protein kinase (MAPK). Oncogene. 17:3157–3167. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Quadros MR, Peruzzi F, Kari C and Rodeck
U: Complex regulation of signal transducers and activators of
transcription 3 activation in normal and malignant keratinocytes.
Cancer Res. 64:3934–3939. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tkach M, Rosemblit C, Rivas MA, Proietti
CJ, Díaz Flaqué MC, Mercogliano MF, Beguelin W, Maronna E, Guzmán
P, Gercovich FG, et al: p42/p44 MAPK-mediated Stat3Ser727
phosphorylation is required for progestin-induced full activation
of Stat3 and breast cancer growth. Endocr Relat Cancer. 20:197–212.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sengupta TK, Talbot ES, Scherle PA and
Ivashkiv LB: Rapid inhibition of interleukin-6 signaling and Stat3
activation mediated by mitogen-activated protein kinases. Proc Natl
Acad Sci USA. 95:11107–11112. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kovarik P, Stoiber D, Eyers PA, Menghini
R, Neininger A, Gaestel M, Cohen P and Decker T: Stress-induced
phosphorylation of STAT1 at Ser727 requires p38 mitogen-activated
protein kinase whereas IFN-gamma uses a different signaling
pathway. Proc Natl Acad Sci USA. 96:13956–13961. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xue P, Zhao Y, Liu Y, Yuan Q, Xiong C and
Ruan J: A novel compound RY10-4 induces apoptosis and inhibits
invasion via inhibiting STAT3 through ERK-, p38-dependent pathways
in human lung adenocarcinoma A549 cells. Chem Biol Interact.
209:25–34. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Song IS, Jun SY, Na HJ, Kim HT, Jung SY,
Ha GH, Park YH, Long LZ, Yu DY, Kim JM, et al: Inhibition of
MKK7-JNK by the TOR signaling pathway regulator-like protein
contributes to resistance of HCC cells to TRAIL-induced apoptosis.
Gastroenterology. 143:1341–1351. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tang RX, Kong FY, Fan BF, Liu XM, You HJ,
Zhang P and Zheng KY: HBx activates FasL and mediates HepG2 cell
apoptosis through MLK3-MKK7-JNKs signal module. World J
Gastroenterol. 18:1485–1495. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sau A, Filomeni G, Pezzola S, D'Aguanno S,
Tregno FP, Urbani A, Serra M, Pasello M, Picci P, Federici G and
Caccuri AM: Targeting GSTP1-1 induces JNK activation and leads to
apoptosis in cisplatin-sensitive and -resistant human osteosarcoma
cell lines. Mol Biosyst. 8:994–1006. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chen B, Liu J, Chang Q, Beezhold K, Lu Y
and Chen F: JNK and STAT3 signaling pathways converge on
Akt-mediated phosphorylation of EZH2 in bronchial epithelial cells
induced by arsenic. Cell Cycle. 12:112–121. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chen F: JNK-induced apoptosis,
compensatory growth, and cancer stem cells. Cancer Res. 72:379–386.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bubici C and Papa S: JNK signalling in
cancer: In need of new, smarter therapeutic targets. Br J
Pharmacol. 171:24–37. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Seki E, Brenner DA and Karin M: A liver
full of JNK: Signaling in regulation of cell function and disease
pathogenesis, and clinical approaches. Gastroenterology.
143:307–320. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Leventaki V, Drakos E, Medeiros LJ, Lim
MS, Elenitoba-Johnson KS, Claret FX and Rassidakis GZ: NPM-ALK
oncogenic kinase promotes cell-cycle progression through activation
of JNK/cJun signaling in anaplastic large-cell lymphoma. Blood.
110:1621–1630. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Jia G, Kong R, Ma ZB, Han B, Wang YW, Pan
SH, Li YH and Sun B: The activation of c-Jun
NH2-terminal kinase is required for
dihydroartemisinin-induced autophagy in pancreatic cancer cells. J
Exp Clin Cancer Res. 33:82014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Shi Y, Nikulenkov F, Zawacka-Pankau J, Li
H, Gabdoulline R, Xu J, et al: ROS-dependent activation of JNK
converts p53 into an efficient inhibitor of oncogenes leading to
robust apoptosis. Cell Death Differ. 21:612–23. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Chen YH, Hao LJ, Hung CP, Chen JW, Leu SF
and Huang BM: Apoptotic effect of cisplatin and cordycepin on OC3
human oral cancer cells. Chin J Integr Med. 20:624–632. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Noutomi T, Itoh M, Toyota H, Takada E and
Mizuguchi J: Tumor necrosis factor-related apoptosis-inducing
ligand induces apoptotic cell death through c-Jun NH2-terminal
kinase activation in squamous cell carcinoma cells. Oncol Rep.
22:1169–1172. 2009.PubMed/NCBI
|
|
48
|
Li Q, Song XM, Ji YY, Jiang H and Xu LG:
The dual mTORC1 and mTORC2 inhibitor AZD8055 inhibits head and neck
squamous cell carcinoma cell growth in vivo and in vitro. Biochem
Biophys Res Commun. 440:701–706. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kim HJ, Chakravarti N, Oridate N, Choe C,
Claret FX and Lotan R: N-(4-hydroxyphenyl)retinamide-induced
apoptosis triggered by reactive oxygen species is mediated by
activation of MAPKs in head and neck squamous carcinoma cells.
Oncogene. 25:2785–2794. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Sakai T, Banno Y, Kato Y, Nozawa Y and
Kawaguchi M: Pepsin-digested bovine lactoferrin induces apoptotic
cell death with JNK/SAPK activation in oral cancer cells. J
Pharmacol Sci. 98:41–48. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zhao L, Yue P, Lonial S, Khuri FR and Sun
SY: The NEDD8-activating enzyme inhibitor, MLN4924, cooperates with
TRAIL to augment apoptosis through facilitating c-FLIP degradation
in head and neck cancer cells. Mol Cancer Ther. 10:2415–2425. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhang S, Wang XL, Gan YH and Li SL:
Activation of c-Jun N-terminal kinase is required for
mevastatin-induced apoptosis of salivary adenoid cystic carcinoma
cells. Anticancer Drugs. 21:678–686. 2010.PubMed/NCBI
|
|
53
|
Hour MJ, Lee KH, Chen TL, Lee KT, Zhao Y
and Lee HZ: Molecular modelling, synthesis, cytotoxicity and
anti-tumour mechanisms of 2-aryl-6-substituted quinazolinones as
dual-targeted anti-cancer agents. Br J Pharmacol. 169:1574–1586.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Chen HM, Liu CM, Yang H, Chou HY, Chiang
CP and Kuo MY: 5-aminolevulinic acid induce apoptosis via NF-κB/JNK
pathway in human oral cancer Ca9-22 cells. J Oral Pathol Med.
40:483–489. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Bhattarai G, Lee YH, Lee NH, Lee IK, Yun
BS, Hwang PH and Yi HK: Fomitoside-K from Fomitopsis nigra
induces apoptosis of human oral squamous cell carcinomas (YD-10B)
via mitochondrial signaling pathway. Biol Pharm Bull. 35:1711–1719.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Li C and Johnson DE: Bortezomib induces
autophagy in head and neck squamous cell carcinoma cells via JNK
activation. Cancer Lett. 314:102–107. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Schramek D, Kotsinas A, Meixner A, Wada T,
Elling U, Pospisilik JA, Neely GG, Zwick RH, Sigl V, Forni G, et
al: The stress kinase MKK7 couples oncogenic stress to p53
stability and tumor suppression. Nat Genet. 43:212–219. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Dai Y, Guzman ML, Chen S, Wang L, Yeung
SK, Pei XY, Dent P, Jordan CT and Grant S: The NF (nuclear
factor)-κB inhibitor parthenolide interacts with histone
deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in
human acute myeloid leukaemia cells. Br J Haematol. 151:70–83.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Lui VW, Peyser ND, Ng PK, Hritz J, Zeng Y,
Lu Y, Li H, Wang L, Gilbert BR, General IJ, et al: Frequent
mutation of receptor protein tyrosine phosphatases provides a
mechanism for STAT3 hyperactivation in head and neck cancer. Proc
Natl Acad Sci USA. 111:1114–1119. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Gkouveris I, Nikitakis N, Karanikou M,
Rassidakis G and Sklavounou A: Erk1/2 activation and modulation of
STAT3 signaling in oral cancer. Oncol Rep. 32:2175–2182.
2014.PubMed/NCBI
|
|
61
|
Kim JH, Lee SC, Ro J, Kang HS, Kim HS and
Yoon S: Jnk signaling pathway-mediated regulation of Stat3
activation is linked to the development of doxorubicin resistance
in cancer cell lines. Biochem Pharmacol. 79:373–380. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Guo W, Wu S, Wang L, Wei X, Liu X, Wang J,
Lu Z, Hollingshead M and Fang B: Antitumor activity of a novel
oncrasin analogue is mediated by JNK activation and STAT3
inhibition. PLoS One. 6:e284872011. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Liu J, Chen B, Lu Y, Guan Y and Chen F:
JNK-dependent Stat3 phosphorylation contributes to Akt activation
in response to arsenic exposure. Toxicol Sci. 129:363–371. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Shirakawa T, Kawazoe Y, Tsujikawa T, Jung
D, Sato S and Uesugi M: Deactivation of STAT6 through serine 707
phosphorylation by JNK. J Biol Chem. 286:4003–4010. 2011.
View Article : Google Scholar : PubMed/NCBI
|
